In Vitro: PIM447 (0.05-10 μM; 24-72 hours) shows antiproliferative effect on the multiple myeloma (MM) cells. PIM447 (10 μM; 6-24 hours) induces apoptosis. PIM447 (0.1-10 μM; 48 hours) increases the percentage of cells in the G0-G1 phase and decreases the proliferative phases (S and G2–M) of the cell cycle, in the two cell lines (MM1S and OPM-2 cells) at all doses.
In Vivo: PIM447 (100 mg/kg; p.o.; 5 times for a week) reduces tumor burden.